Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Theratechnologies Inc
(TSX:
TH
)
1.730
+0.030 (+1.76%)
Streaming Delayed Price
Updated: 3:01 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
11,700
Open
1.700
Bid (Size)
1.700 (109)
Ask (Size)
1.730 (325)
Prev. Close
1.700
Today's Range
1.700 - 1.730
52wk Range
1.260 - 4.450
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
July 10, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
June 26, 2024
From
Theratechnologies
Via
GlobeNewswire
Performance
YTD
-23.11%
-23.11%
1 Month
-11.73%
-11.73%
3 Month
+4.22%
+4.22%
6 Month
-14.36%
-14.36%
1 Year
+37.30%
+37.30%
More News
Read More
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
May 23, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Reports on its Annual Meeting of Shareholders
May 09, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
May 02, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
April 15, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 11, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
April 10, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
April 08, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Appoints Elina Tea to its Board of Directors
April 05, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
April 03, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
March 28, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Announces Update on its Preclinical Oncology Research Program
March 22, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Appoints Jordan Zwick to its Board of Directors
March 21, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
March 21, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
February 29, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
February 27, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
February 21, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
February 20, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
February 15, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
February 06, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
January 24, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
January 23, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
January 02, 2024
From
Theratechnologies
Via
GlobeNewswire
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
December 13, 2023
From
Theratechnologies
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.